Home > Neurology > EAN 2020 > Headache and Pain > Fremanezumab tolerability in cardiovascular patients with migraine

Fremanezumab tolerability in cardiovascular patients with migraine

Presented By
Dr Gianluca Coppola, Sapienza University of Rome, Italy
Conference
EAN 2020
Trial
Phase 3, HALO, FOCUS
In a pooled analysis of 3 phase 3 trials, fremanezumab treatment over 12 weeks was well tolerated, with a low rate of cardiovascular adverse events (AEs) similar to placebo in migraine patients using cardiovascular medication at baseline [1]. There were no new safety signals over 12 weeks of double-blind treatment. Fremanezumab is a a fully-humanised monoclonal antibody that selectively targets calcitonin gene-related peptide. The 3 trials included were HALO EM, HALO CM, and FOCUS, in which patients were randomised to subcutaneous quarterly or monthly fremanezumab, or placebo over 12 weeks. Overall, 280/2,842 trial participants were receiving car...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on